(19)
(11) EP 4 499 638 A1

(12)

(43) Date of publication:
05.02.2025 Bulletin 2025/06

(21) Application number: 23722227.8

(22) Date of filing: 24.03.2023
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 25/00(2006.01)
A61K 31/5025(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 471/04
(86) International application number:
PCT/US2023/064967
(87) International publication number:
WO 2023/183943 (28.09.2023 Gazette 2023/39)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 25.03.2022 US 202217704983
31.10.2022 US 202263420930 P
07.02.2023 US 202363443874 P

(71) Applicant: Ventus Therapeutics U.S., Inc.
Waltham, MA 02453 (US)

(72) Inventors:
  • DORICH, Stéphane
    Pointe-Claire, Québec H9R 1H6 (CA)
  • CHEFSON, Amandine
    Montreal, Québec H4E 2W8 (CA)
  • CIBLAT, Stéphane
    Montreal, Québec H2J 0A2 (CA)

(74) Representative: Schlich 
9 St Catherine's Road Littlehampton
West Sussex BN17 5HS
West Sussex BN17 5HS (GB)

   


(54) PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES